in pictures and a few words
What it is and why it matters
Acoramidis is a tablet for adults in whom a protein from the blood settles in the heart. The tablet keeps this protein whole so that it does not fall apart.
- It suits both the inherited form of the disease and the one that comes with age
- Approved in the USA in November 2024
What goes wrong in this disease
The blood carries a transport protein. Normally it is made of four parts firmly held together. With age, or because of an inherited gene fault, this hold weakens.
- The heart muscle filled with fibres stiffens and relaxes poorly — heart failure develops
- The main measure of heart pumping stays normal — so the disease goes unnoticed for years
A hint from nature
Some people have a special variant of the gene for this protein. Their protein holds together more firmly than usual, and they do not develop the disease — even if they also carry a second, disease-causing fault.
- The tablet was designed to copy this natural protection: it holds the four parts of the protein together
Tested in people with this disease
In a large study of adults with this heart disease, the tablet was compared with a dummy pill. The result favoured the tablet.
- More than half of the advantage came from deaths and hospital stays due to heart and blood vessels
- These matter in themselves, not just as lab numbers
Tested in people. Tested in people: a large study in adults with this heart disease.
How the “wins” were counted
People from the two groups were compared in pairs — one step at a time, from the most important to the less important.
- First — who lived longer, then — who was less often in hospital due to heart and blood vessels
- Next — a blood test for heart failure and who walked farther in six minutes
- The tablet had clearly more wins than losses
Tolerated like a dummy pill
Unwanted effects on the tablet were as common as on the dummy pill. Serious ones were even less common.
- There were fewer serious ones because on the dummy pill the disease progressed faster and caused complications
Tested in people. Tested in people: in the same large study.
How to take it
These are tablets. The cardiologist sets the schedule — once the diagnosis is confirmed.
- The tablet adds to the usual treatment of heart failure, it does not replace it
- The earlier treatment starts, the more healthy heart muscle can be protected
- With long-term use the benefit holds
When to suspect the disease
Be alert if an older person has heart failure, the main measure of heart pumping is normal, and the heart walls are thickened for no clear reason.
- A pinched nerve in the wrists of both hands — several years before heart problems
- Narrowing of the spinal canal, a torn shoulder muscle tendon
- Usual heart medicines are poorly tolerated, especially those that lower blood pressure
Important. The diagnosis is made without a heart biopsy — by a special scan. Another type of amyloidosis must be ruled out: it is treated quite differently.
Who should see a doctor first
The tablet is started only when the diagnosis is confirmed — after the scan and ruling out other causes, not on suspicion.
- Not suitable for light-chain amyloidosis: it is a different disease with different treatment
- The tablet does not replace the main treatment of heart failure
Important. In light-chain amyloidosis, delay costs more — first an accurate diagnosis.
In one sentence
The tablet copies a natural protection: it keeps the protein whole so that fewer new fibres form in the heart — and in a large study the result favoured the tablet.
- The earlier the diagnosis is made, the more healthy heart muscle can be saved
Key Points
Acoramidis (Attruby) is a tablet for adults with transthyretin amyloid cardiomyopathy, in both its hereditary and its age-related form. It keeps the transthyretin protein from falling apart; approved by the FDA in November 2024.
| Situation | How it helps | What human studies showed |
|---|---|---|
| Transthyretin amyloid cardiomyopathy | holds transthyretin together and thereby slows the formation of new amyloid | ATTRibute-CM (NEJM, 2024), 632 patients, 30 months: the primary outcome favoured the drug, win ratio 1.8 (95% CI 1.4–2.2; p<0.001); more than half the contribution came from death from any cause and cardiovascular hospitalisation — outcomes that matter in themselves [1] |
| Tolerability | adverse events as on placebo, serious ones less frequent | 98.1% versus 97.6%; serious — 54.6% versus 64.9% [1] |
| Long-term treatment | the effect holds | open-label extension of ATTRibute-CM (JAMA Cardiology, 2026) [2] |
How It Helps
What Happens to the Heart
Transthyretin is an ordinary blood protein carrying thyroid hormone and vitamin A. Normally it is assembled from four identical parts locked firmly together.
With age, or because of an inherited mutation, that lock weakens. The structure falls apart, the loose parts change shape and clump into insoluble fibrils — amyloid.
Those fibrils deposit in the heart muscle. It becomes stiff and stops relaxing properly: the heart cannot fill adequately between beats. Heart failure develops — and its distinguishing feature is that ejection fraction stays normal, which is why the disease slips past diagnosis for years.
The Hint Nature Provided
There is a variant of the transthyretin gene called T119M. In its carriers the protein holds together more firmly than usual. And — the key fact — they do not develop amyloidosis, even when a second, disease-causing mutation is present.
The experiment, in other words, has already been run: nature itself showed that if the tetramer is not allowed to fall apart, the disease does not occur.
Acoramidis is engineered to reproduce that effect chemically: it binds the four parts of the protein and holds them together. This is the rare case of a drug that was not invented from scratch but copied from an existing protection.
What the Trial Showed
▸ATTRibute-CM: 63.7% of pairwise comparisons favoured the drug against 35.9% favouring placebo [1].
Serious events were less frequent on the drug, and the explanation is straightforward: in the placebo group the disease progressed faster, and its complications are precisely what counts as serious events.
What a Win Ratio Is and Why It Was Needed
When several outcomes matter and they are not equivalent, they cannot simply be added up: a death and metres walked in six minutes are quantities of different orders. So patients from the two groups are compared in pairs and in a strict order:
| Step | What is compared |
|---|---|
| 1 | Who lived longer |
| 2 | If there is no difference — who had fewer cardiovascular hospitalisations |
| 3 | If still equal — whose NT-proBNP was better |
| 4 | Last — who walked further in six minutes |
Each pair yields a win or a loss. A win ratio of 1.8 means the drug produced 1.8 times as many wins as losses. The point of the construction is to stop small improvements from outweighing deaths, by ranking outcomes in the order of their real importance.
Where It Sits Among Other Drugs
| Tafamidis | Acoramidis | |
|---|---|---|
| Class | Transthyretin stabiliser | Transthyretin stabiliser |
| Pivotal trial | ATTR-ACT (2018) | ATTRibute-CM (2024) |
| Form | Capsules | Tablets |
Both drugs act at the same point.
How It Is Taken
Tablets; the regimen is prescribed by the cardiologist according to the prescribing information [4], once the diagnosis is confirmed. Acoramidis adds to baseline heart failure therapy. The earlier treatment starts, the more intact heart muscle can be protected.
Who Should See a Doctor First
When to Suspect the Disease
▸Heart failure in an older person with preserved ejection fraction and unexplained thickened heart walls. ▸Bilateral carpal tunnel syndrome occurring some years before the cardiac symptoms — one of the most characteristic early signs. ▸Spinal canal stenosis, rupture of the biceps tendon. ▸Poor tolerance of standard cardiac drugs, particularly those lowering blood pressure.
The diagnosis today is made without a cardiac biopsy, using scintigraphy with bone-seeking tracers. One condition is mandatory: excluding light-chain amyloidosis, which is treated in an entirely different way.
Who It Is Not For
▸Patients with light-chain amyloidosis: a different disease with different treatment, where delay costs more. ▸Anyone without a confirmed diagnosis: treatment begins after scintigraphy and the exclusion of alternatives, not on suspicion. ▸As a replacement for baseline heart failure therapy — a stabiliser adds to it rather than cancelling it.
Bottom Line
▸Mechanism: holds transthyretin together, copying the naturally protective T119M mutation. ▸Demonstrated in 632 patients: a win ratio of 1.8, with more than half the contribution from deaths and hospitalisations. ▸Early diagnosis decides the outcome: the drug protects intact muscle — the earlier treatment starts, the more of it can be preserved.
Treatment can be discussed at a consultation; the drug can be ordered here.
References
1. Gillmore JD, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024;390(2):132–142. PMID 38197816
2. Soman P, et al. Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Trial. JAMA Cardiol. 2026;11(5):446–454. PMID 41911489
3. Maurer MS, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. PMID 30145929
4. ATTRUBY (acoramidis) — US Prescribing Information, BridgeBio Pharma.
Caveats
What cannot be claimed yet:
▸That it is better or worse than tafamidis — no head-to-head data exist: both were compared only with placebo, and matching up separate trials with different participants is not valid. The choice between them is a matter of availability and clinical situation. ▸That it dissolves amyloid already deposited: the drug obstructs the formation of new fibrils, it does not remove old ones. ▸That it helps at any stage: the more muscle already affected, the less there is left to protect. ▸That it affects other types of amyloidosis — the indication covers the transthyretin form only.
This material is for information only and does not replace a consultation with a doctor.
Key facts
- Acoramidis (brand name Attruby, BridgeBio) is an oral transthyretin stabiliser approved by the FDA in November 2024 for transthyretin amyloid cardiomyopathy in adults.
- The molecule was designed after the natural T119M mutation: in its carriers transthyretin is unusually stable and amyloidosis does not develop — nature had already shown the approach works.
- ATTRibute-CM (NEJM, 2024): 632 patients over 30 months; the hierarchical composite outcome favoured the drug (p<0.001) with a win ratio of 1.8 (95% CI 1.4–2.2). More than half of that result came from death from any cause and cardiovascular hospitalisation — outcomes that matter in themselves rather than surrogate measures.
- Adverse events occurred at the same rate as on placebo (98.1% versus 97.6%), and serious ones were less frequent: 54.6% versus 64.9%. An open-label extension (JAMA Cardiology, 2026) confirmed that the effect holds with long-term treatment.
- The disease was long considered rare, but it is increasingly found in older people with heart failure and preserved ejection fraction — diagnosed by scintigraphy, without a cardiac biopsy.
